Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.

Hassan, Eman; Jonathan, Lancashire; Jayashree, Motwani

Hassan, Eman; Jonathan, Lancashire; Jayashree, Motwani.

Afiliación

Hassan E; Department of Paediatrics, NHS Foundation Trust, Paediatric Haematology, Haematology and Oncology Unit, Birmingham Children's Hospital, Birmingham, UK.
Jonathan L; Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children's Hospital, Birmingham, UK.
Jayashree M; Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children's Hospital, Birmingham, UK.

Haemophilia ; 27(6): e698-e703, 2021 Nov.

Article en En | MEDLINE | ID: mdl-34628693

Asunto(s)

Anticuerpos Biespecíficos; Hemofilia A; Anticuerpos Monoclonales Humanizados/uso terapéutico; Niño; Factor VIII/antagonistas & inhibidores; Hemofilia A/tratamiento farmacológico; Hemorragia/etiología; Hemorragia/prevención & control; Humanos

Palabras clave

TOLERABILITY; adverse events; emicizumab; paediatrics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Hemofilia A Tipo de estudio: Etiology_studies Idioma: En Revista: Haemophilia Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google